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ABSTRACT
Introduction: Due to the high prevalence of
actinic keratosis (AK) and potential for lesions
to become cancerous, clinical guidelines
recommend that all are treated. The objective
of this study was to evaluate the efficacy and
safety of 5-fluorouracil (5-FU) 0.5%/salicylic
acid 10% as field-directed treatment of AK
lesions.
Methods: This multicenter, double-blind,
vehicle-controlled study (NCT02289768)
randomized adults, with a 25 cm2 area of skin
on their face, bald scalp, or forehead covering
4–10 clinically confirmed AK lesions (grade I/II),
2:1 to treatment or vehicle applied topically
once daily for 12 weeks. The primary endpoint
was the proportion of patients with complete
clinical clearance (CCC) of lesions in the
treatment field 8 weeks after the end of
treatment. Secondary endpoints included
partial clearance (PC; C75% reduction) of
lesions. Safety outcomes were assessed.
Results: Of 166 patients randomized, 111
received 5-FU 0.5%/salicylic acid 10% and 55
received vehicle. At 8 weeks after the end of
treatment, CCC was significantly higher with
5-FU 0.5%/salicylic acid 10% than with vehicle
[49.5% vs. 18.2%, respectively; odds ratio (OR)
3.9 (95% CI) 1.7, 8.7; P = 0.0006]. Significantly
more patients achieved PC of lesions with
treatment than with vehicle [69.5% vs. 34.6%,
respectively; OR 4.9 (95% CI 2.3, 10.5);
P\0.0001]. Treatment-emergent adverse
events, predominantly related to application-
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and administration-site reactions, were more
common with 5-FU 0.5%/salicylic acid 10%
than with vehicle (99.1% vs. 83.6%).
Conclusions: Compared with vehicle,
field-directed treatment of AK lesions with
5-FU 0.5%/salicylic acid 10% was effective in
terms of CCC. Safety outcomes were consistent
with the known and predictable safety profile.
Trial registration: NCT02289768.
Funding: Almirall S.A.





Actinic keratosis (AK) is a common skin
condition characterized by dysplastic lesions of
keratinocytes that have the potential to become
malignant [1, 2]. Infiltrative transformation of
AK grade III lesions to invasive squamous cell
carcinoma (SCC) was believed to occur via a
classical pathway involving sequential
progression from grade I through to grade III
AK. However, recent findings indicate that
invasive SCC can expand directly from a grade
I AK lesion [3]. Owing to the high prevalence of
AK, the risk of lesions becoming cancerous, and
the inability to predict which lesions will
progress to SCC, this justifies the treatment of
all AK lesions regardless of grade [4, 5].
Current options for the topical treatment of
AK lesions include diclofenac, hyaluronic acid,
5-fluorouracil (5-FU), imiquimod, and ingenol
mebutate [6–8]. Lesion- or field-directed therapy
is indicated subject to the specific
characteristics of the lesions to be treated
(e.g., their number, localization, extent, and
clinical course) and patient features (e.g., age,
comorbidities, and other risk factors) [9, 10].
Historically, lesion-directed treatments have
been the most common approach for treating
a single lesion, whereas field-directed therapies,
which aim to treat areas with multiple AK
lesions of varying degrees of severity,
including sub-clinical (non-visible) lesions [9],
are now preferred if lesion and patient
characteristics permit [11].
5-FU 0.5%/salicylic acid 10% (Actikerall,
Almirall S.A.) is indicated for the topical
treatment of slightly palpable and/or
moderately thick hyperkeratotic AK lesions
(grade I/II according to Olsen et al. 1991 [12])
in immunocompetent adults, with an option to
simultaneously treat multiple AK lesions, up to
a maximum of 10 lesions in a total skin area of
25 cm2 [13]. However, only a maximum rim of
0.5 cm of healthy skin surrounding the lesions
can come into contact with 5-FU 0.5%/salicylic
acid 10%.
Here we report new efficacy and safety data
from the first randomized controlled trial
investigating the efficacy and safety of 5-FU
0.5%/salicylic acid 10% when applied as
field-directed treatment to a contiguous area of
25 cm2 in a field cancerization area on the face,
bald scalp, or forehead of patients with 4–10
clinically confirmed AK lesions (grade I and II).
METHODS
Study Design and Ethical Conduct
This phase III, multicenter, randomized,
double-blind, vehicle-controlled study
(ClinicalTrials.gov identifier: NCT02289768)
was conducted at 14 sites in Germany and the
UK. There were five treatment visits and a
follow-up visit 8 weeks after the final
treatment application, regardless of whether a
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patient had completed 12 weeks of treatment or
prematurely discontinued from treatment
(Fig. 1). Findings from a sub-study that
examined the effect of 5-FU 0.5%/salicylic acid
10% on sub-clinical AK lesions using reflectance
confocal microscopy (RCM) in a group of 30
patients will be published separately.
The study was conducted in accordance with
the recommendations of the Helsinki
Declaration of 1964, as revised in 2008,
complied with International Conference on
Harmonisation Good Clinical Practice
guidelines and local regulations and was
approved by an independent ethics
committee. Informed consent was obtained
from all patients in writing prior to inclusion
in the study.
Patients
Male and female (non-pregnant, non-lactating
in the last 3 months) patients were enrolled in
the study if they were aged 18–85 years and had
4–10 clinically confirmed AK lesions (grade I/II
[12]) within a field cancerization area of 25 cm2
located on the face, bald scalp, or forehead.
Patients had Fitzpatrick skin type I–IV, were in
good health and were free of physical and
mental conditions that could interfere with
the examination or evaluation of the potential
treatment area. During the study, patients had
to refrain from sunbathing and avoid intense
ultraviolet-light exposure/solarium. They also
had to avoid the use of moisturizers and topical
treatments with anti-aging products, ointments
containing vitamins A, C, and/or E, and gels
and green-tea preparations in the treatment
area. Patients also had to be physically able (or
have a supportive person) to apply the study
preparations correctly and to follow the study
procedure and restrictions.
Key exclusion criteria included patients
who B3 months before screening had received
treatment for AK within the treatment area or if
they had dermatological diseases in the
treatment area or surrounding area that could
be exacerbated by study treatment or could
interfere with the study assessments (e.g.,
psoriasis, eczema). Additionally, patients were
excluded if they had received topical treatment
with certain pharmacological and
non-pharmacological products (e.g., retinoids,
steroids, diclofenac or 5-FU preparations,
curettage, photodynamic therapy, and
5-FU 0.5% / salicylic acid 10%*
Vehicle*
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Fig. 1 Study design. *Once-daily topical administration. 5-FU 5-ﬂuorouracil, V visit
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chemical peel) in the treatment area 4–8 weeks
(depending on the product) prior to
randomization. Patients were also excluded if
they had received systemic medication (varying
between 4 and 12 weeks, depending on the
medication), including: interferons;
immunomodulators or immunosuppressive
drugs; diclofenac or 5-FU preparations; and
cytotoxic drugs. The use of phenytoin,
methotrexate, or sulfonylurea was also not
allowed.
Treatment
At visit 2, patients were randomized 2:1 in
ascendant chronological order to receive topical
5-FU 0.5%/salicylic acid 10% or colour/
consistency/appearance-matched vehicle,
which was self-administered once daily for 12
weeks using a brush enclosed in the cap of the
medication container. This was a double-blind
study so neither the patient nor the research
personnel knew the treatment assigned to each
patient.
Study medication was applied at the same
time each day according to the instructions in
the product patient leaflet, except that the area
of application was a contiguous 25 cm2. The
dose regimen could be decreased by the
physician to three doses per week in the case
of severe local skin reactions. Treated areas were
left uncovered, and study medication was
allowed to dry to enable a film to form over
the area. Prior to daily re-application of the
medication, the film coating was peeled off and
the skin washed with water and a damp cloth.
Patients were instructed to not apply
medication to bleeding lesions.
The location of the treated area was chosen
according to the ability of the patient to
conveniently apply study medication on a
daily basis. A plastic template was used to
mark and later identify the same 25 cm2
treated area. The first and final treatment
applications were performed at the study
center by study staff.
Study Assessments and Endpoints
The primary endpoint was the proportion of
patients with complete clinical clearance (CCC)
of AK lesions in the treatment field at 8 weeks
after the end of treatment. CCC of AK lesions at
each treatment visit (i.e., after 2, 4, 6, and
12 weeks of treatment) was measured as a
secondary endpoint. Additional secondary
endpoints reporting the effect of treatment on
lesions included: partial clearance (PC; defined
as C75% reduction in clinically visible AK
lesions) at each treatment visit and 8 weeks
after the end of treatment; proportional change
from baseline in the total number of AK lesions
at each treatment visit and 8 weeks after the end
of treatment; the number of lesions by AK grade
severity at baseline and 8 weeks after the end of
treatment; and proportional change from
baseline in the total number of lesions at each
treatment visit and 8 weeks after the end of
treatment.
A physician-reported outcome was global
assessment of efficacy [Physician Global
Assessment (PGA)] at each treatment visit and
8 weeks after the end of treatment.
Patient-reported outcomes included patient
satisfaction with treatment by recording
individual domain scores (i.e., effectiveness,
side effects, convenience, and overall
satisfaction) of the Treatment Satisfaction
Questionnaire for Medication (TSQM, version
1.4) at 8 weeks after the end of treatment and
quality-of-life assessment by recording the
change from baseline in total and individual
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domain scores (i.e., daily activities, leisure,
personal relationships, symptoms and feelings,
treatment, work, and school) of the
Dermatology Life Quality Index (DLQI) after
12 weeks of treatment and at 8 weeks after the
end of treatment. DLQI was calculated by
summing the score of each question resulting
in a maximum of 30 and a minimum of 0, and
the higher the score, the more quality of life is
impaired.
Adverse events (AEs) were collected from the
time of informed consent to the follow-up visit;
this was always performed 8 weeks post last
treatment, regardless of whether the patient
had completed the 12-week treatment period or
had prematurely discontinued from the study.
The reporting of AEs was elicited by asking
patients non-leading questions and by
collecting information regarding the AEs
spontaneously reported by the patients to
study staff.
Statistical Analysis
It was determined that a total of 146 patients
(97 receiving active treatment, 49 receiving
vehicle) was required to complete the study to
provide 80% power to detect as ‘‘significant’’ a
difference of 25% between 5-FU 0.5%/salicylic
acid 10% and vehicle in the proportion of
patients with CCC, assuming a clearance rate
in the active group of 50% and a clearance rate
in the vehicle group of 25%. To allow for an
estimated 10% dropout rate, approximately
162 patients (108 receiving treatment, 54
receiving vehicle) were to be randomized.
The primary endpoint (CCC) comparison of
5-FU 0.5%/salicylic acid 10% versus vehicle was
analyzed using the Cochran-Mantel-Haenszel
test statistic adjusting for anatomical site (face/
scalp) and baseline (number of AK lesions). The
number and proportion of responders for each
treatment group, odds ratio (OR),
corresponding 95% confidence interval (CI),
and the two-sided P value associated with the
Cochran-Mantel-Haenszel test were calculated.
The 95% CI for the proportion of patients with
CCC was calculated using the exact binomial
test.
The secondary endpoint of the proportion of
patients with CCC of AK lesions in the
treatment field at each treatment visit was
analyzed in the same way as the primary
efficacy variable. Other secondary endpoints
and safety data were analyzed using
descriptive statistics. Missing efficacy data were
handled using the last observation carried
forward (LOCF). An analysis of covariance
model with treatment arm and anatomical site
as factors and baseline as covariate was used for
the analysis of total and individual domain
scores of the TSQI and DLQI. All secondary
endpoints were analyzed using the
intent-to-treat (ITT) population only.
RESULTS
Patients
This study was conducted between 17 October
2014 and 10 August 2015. Of the 175 patients
screened, 166 were randomized. Of these, 111
patients received 5-FU 0.5%/salicylic acid 10%
(108 patients in the safety and ITT
populations) and 55 patients received vehicle
(Fig. 2).
Baseline demographics were similar between
the groups, with slightly more female patients
in the active treatment arm (14.8%) versus
vehicle (7.3%; Table 1). At baseline, 56.6% of
lesions were classified as grade I and 43.4% were
classified as grade II; similar ratios of grade I and
grade II AK lesions were present in each
treatment arm.
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Efficacy
The percentage of patients with CCC 8 weeks
after the end of treatment (primary endpoint)
was significantly higher in the 5-FU 0.5%/
salicylic acid 10% arm compared with vehicle
in both the ITT andper protocol (PP) populations
[ITT LOCF: 49.5% vs. 18.2%; OR 3.9 (95% CI 1.7,
8.7) P = 0.0006 (Fig. 3a); PP LOCF: 55.1% vs.
19.6%; OR 5.1 (95% CI 2.1, 12.2) P = 0.0002].
During treatment, there were no significant
differences between 5-FU 0.5%/salicylic acid
10% and vehicle (Fig. 3b); however, it should be
noted that it can be difficult to assess lesion
counts during treatment because of irritation at
the site of administration.
Eight weeks after the end of treatment, the
proportion of patients who achieved PC of AK
lesions was significantly greater in the 5-FU
0.5%/salicylic acid 10% arm than in the vehicle
arm [69.5% vs. 34.6%; OR 4.9 (95% CI 2.3, 10.5)
P\0.0001 (Fig. 4)]. The proportional reduction
from baseline in the total number of AK lesions
per patient was significantly greater with 5-FU
0.5%/salicylic acid 10% than with vehicle:
78.0% versus 46.9%, respectively; P\0.0001
(Fig. 5). For both PC and reduction in lesion
count, there were no significant differences
between the treatment groups at each visit of
the 12-week treatment period. At 8 weeks after
the end of treatment, a higher proportion of AK
lesions in the active treatment arm had
transitioned from grade I/II to grade 0
compared with the vehicle arm (Fig. 6).
Assessment of treatment efficacy according
to PGA found that for 5-FU 0.5%/salicylic acid
175 patients screened Excluded, n = 9
Did not meet inclusion/
exclusion criteria: n = 1








Per protocol: 89 (80.2%)
Populations
Discontinued treatment: 15 (13.5%)b Discontinued treatment: 5 (9.1%)b





Adverse event: 2 (1.8%)
Protocol violation: 1 (0.9%)
Withdrawal by patients: 12 (10.8%)
Adverse event: 0 (0.0%)
Lost follow-up: 1 (0.9%)
Withdrawal by patient: 5 (4.5%)
Safety: 55 (100.0%)
Intent-to-treat: 55 (100.0%)
Per protocol: 46 (83.6%)
Adverse event: 2 (3.6%)
Protocol violation: 1 (1.8%)
Withdrawal by patient: 2 (3.6%)
Adverse event: 1 (1.8%)
Lost to follow-up: 0 (0.0%)
Withdrawal by patient: 1 (1.8%)
Fig. 2 Patient disposition. a Includes 3 patients who were
counted only as randomized; b overall, 12 patients
prematurely discontinued treatment but completed
follow-up: 5-FU/SA, n = 9; vehicle, n = 3. c All patients
who discontinued follow-up also discontinued treatment:
5-FU/SA, n = 6; vehicle, n = 2. 5-FU/SA 5-ﬂuorouracil
0.5%/salicylic acid 10%
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10%, those with a PGA score of ‘‘good’’ or ‘‘very
good’’ increased from 45.2% at week 2 to 90.2%
at follow-up (Fig. 7). In contrast, this increased
from 61.1% at week 2 to no more than 75.5% at
follow-up for vehicle (P\0.0001).
At 8 weeks after the end of treatment, 5-FU
0.5%/salicylic acid 10% was associated with
significant improvements in overall treatment
satisfaction and effectiveness domain mean
scores in the TSQM compared with vehicle
[69.2 vs. 56.1 (P = 0.0019); 70.8 vs. 59.2
(P = 0.0064), respectively]. No statistically
significant differences were observed between
the study arms for the TSQM convenience (70.7
and 71.2, respectively) and side effect (92.4 and
96.4, respectively) domain scores.
The clinical impact of AK lesions on the
DLQI individual domains at baseline was low,
with symptoms and feelings being the most
affected. As shown in Table 2, improvement in
DLQI total score was statistically greater for
vehicle versus 5-FU 0.5%/salicylic acid 10%
during the treatment phase; this was
attributed to local skin reactions associated
with 5-FU 0.5%/salicylic acid 10%. However,
the improvement in DLQI total score switched
in favor of 5-FU 0.5%/salicylic acid 10% 8 weeks
after the end of treatment, although this was
not statistically significant (P = 0.0725; Table 2;
Supplementary Fig. S1).
Safety
The incidence of treatment-emergent AEs
(TEAEs) was slightly higher in the 5-FU 0.5%/
salicylic acid 10% study arm compared with
Table 1 Patient baseline demographics and clinical characteristics (safety population)
5-FU/SA (N5 108) Vehicle (N5 55) Total (N5 163)
Age, years (mean, SD) 71.8 (7.3) 72.8 (6.9) 72.2 (7.1)
Gender, male (%) 85.2 92.7 87.7
Race, Caucasian (%) 100 100 100
BMI, kg/m2 (mean, SD) 27.5 (3.8) 27.2 (3.9) 27.4 (3.8)
Proportion of AK lesions by grade (Olsen et al. [12]) (%)
Grade I 56.1 57.6 56.6
Grade II 43.9 42.4 43.4
Skin type (Fitzpatrick) (%)
Type I 8.3 9.1 8.6
Type II 78.7 83.6 80.4
Type III 12.0 7.3 10.4
Type IV 0.9 0.0 0.6
Number of AK lesions (mean, SD) 5.6 (1.4) 5.6 (1.5) 5.6 (1.4)
Location of AK lesions (%)
Bald scalp 44.7 46.3 45.2
Face/forehead 55.3 53.7 54.8
AK actinic keratosis, BMI body mass index, 5-FU/SA 5-ﬂuorouracil 0.5%/salicylic acid 10%, SD standard deviation
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vehicle (99.1% vs. 83.6%, respectively)
(Table 3). This was predominantly a
consequence of application- and
administration-site reactions, occurring in
99.1% and 76.4% of respective patients in the
active treatment and vehicle arms; the majority
of these were of mild or moderate intensity.
Nine (5.4%) patients had 11
treatment-emergent serious AEs (TESAEs): in
the 5-FU 0.5%/salicylic acid 10% arm, 6 (5.6%)
patients had a total of 8 TESAEs, and, in the
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Fig. 3 Proportion of patients with complete clinical
clearancea of AK lesions in the treatment ﬁeld a at 8 weeks
after the end of treatment (intent-to-treat population) and
b during treatment (after 2, 4, 6, and 12 weeks) and
8 weeks after the end of treatment (intent-to-treat
population). *P = 0.0006. Analysis was performed using
the Cochran-Mantel-Haenszel test, adjusting for anatomical
site and baseline. The last observation carried forward was
used for missing data; however, for 5-FU/SA, three patients
had only baseline data available so it was not possible to
replace the missing data. a Complete clinical clearance
deﬁned as all lesions cleared and lesion count of zero at
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Week 6Week 4Week W2 eek 12
Fig. 4 Proportion of patients with partial clearancea of
AK lesions in the treatment ﬁeld during treatment (after 2,
4, 6, and 12 weeks) and 8 weeks after the end of treatment
(intent-to-treat population). *P\0.0001. a Partial
clearance deﬁned as B75% reduction in the number of
clinically visible AK lesions. 5-FU/SA 5-ﬂuorouracil 0.5%/





































last treatment Week 6 Week 12Week 4Week 2
5-FU/SA (n = 108) 
Vehicle (n = 55)
Fig. 5 Proportional change from baseline in the total
number of AK lesions recorded during treatment (after 2,
4, 6, and 12 weeks) and at 8 weeks after the end of
treatment (intent-to-treat population). *P\0.0001. 5-FU/
SA 5-ﬂuorouracil 0.5%/salicylic acid 10%, AK actinic
keratosis
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Treatment was discontinued as a result of a
TEAE in two (1.9%) patients in the 5-FU 0.5%/
salicylic acid 10% study arm; no patients in the
vehicle arm discontinued treatment because of
TEAEs. One discontinuation was because of
application-site bleeding, which was deemed to
be related to treatment, and one discontinuation
was because of bladder neoplasm, which was not
deemed to be treatment related. There were no
deaths during the study.
DISCUSSION
Field-directed treatment of AK may offer the
most effective means of eliminating both
clinical and subclinical lesions, thereby
preventing progression to invasive SCC [14].
Our study, the first randomized controlled
trial of field-directed therapy with 5-FU/SA,
showed that field-directed treatment of AK
lesions with 5-FU 0.5%/salicylic acid 10%
applied once daily via topical administration
for 12 weeks was associated with significantly
higher rates of CCC at 8 weeks after the end of
treatment compared with vehicle. PC of AK
lesions and the proportional reduction from
baseline in total number of AK lesions
followed similar trends. In addition, at 8
weeks after the end of treatment, the severity
of AK lesions was reduced to a greater extent
with 5-FU 0.5%/salicylic acid 10% than with
vehicle.
5-FU/SA (n = 606)
Vehicle (n = 309)
5-FU/SA (n = 575)





















































Grade 0 Grade I Grade II





No lesion present, neither visible nor palpable
Flat, pink maculae without signs of hyperkeratosis and erythema, but
with slight palpability; lesions are more easily felt than seen
Pink to reddish papules and erythematous plaques with hyperkeratotic
surface; moderately thick lesions that are easily seen and felt
Very thick and/or obvious actinic keratosis
a
b
Fig. 6 Proportion of AK lesions by severity a(according to Olsen et al. [12]) at a baseline and b 8 weeks after the end of
treatment (intent-to-treat population). a 5-FU/SA 5-ﬂuorouracil 0.5%/salicylic acid 10%, AK actinic keratosis
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The efficacy of 5-FU 0.5%/salicylic acid 10%
applied as lesion-directed therapy for a
maximum of 12 weeks with 8-week follow-up
was explored previously in a phase III study in
which it was used for the treatment of patients
with AK lesions of similar grade and location to
those in the present study [15]. In the previous
study, histological clearance at 8 weeks, the
primary study objective, was achieved in
72.0% of patients, a significantly higher rate
than that achieved following treatment with
diclofenac 3% in hyaluronic acid (59.1%;
P\0.01) and vehicle (44.8%; P\0.0001).
Low-dose 5-FU 0.5%/salicylic acid 10% was
also superior to diclofenac 3% in hyaluronic
acid and vehicle in terms of CCC (55.4% vs.
32.0% and 15.1% for diclofenac 3% in
hyaluronic acid and vehicle, respectively;
P\0.001 for both comparisons). In a
12-month follow-up study [16], the percentage
of sustained clearance of AK lesions was higher
for 5-FU 0.5%/salicylic acid 10% (85.8%) versus
diclofenac 3% in hyaluronic acid (81.0%;
P = 0.02) and vehicle (79.8%; P = 0.04).
A recent review of topical treatments for AK
lesions suggested that 5-FU 0.5%/salicylic acid
10% was associated with a higher incidence of
CCC than imiquimod 2.5% and 3.75% and
ingenol mebutate [17]. It should be noted that
the 5-FU 0.5%/salicylic acid 10% treatment
group also included patients with
hyperkeratotic lesions, which are more severe
and have a potentially higher rate of malignant
transformation [18, 19]; these were not
included in the imiquimod and ingenol
mebutate studies [17]. Longer-term clinical
trials need to be carried out to validate these
findings.
At the end of the active treatment period,
lesion counts were similar between 5-FU 0.5%/
salicylic acid 10% and vehicle arms, a finding










































































Fig. 7 Global assessment of efﬁcacy by physician at each
treatment visit (after 2, 4, 6, and 12 weeks) and 8 weeks
after the end of treatment (intent-to-treat population).
*P\0.0001 (5-FU/SA vs. vehicle). 5-FU/SA 5-ﬂuorouracil
0.5%/salicylic acid 10%
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in lesion assessment caused by irritation at the
site of administration of both 5-FU/SA and
vehicle. However, it is also possible that
vehicle itself may have had a mild therapeutic
effect mediated via an unknown mechanism;
DMSO has a known irritant effect [13] and may
thus activate the skin’s defense mechanisms
[15]. Eight weeks following the end of
treatment, 5-FU 0.5%/salicylic acid 10% was
associated with a significant 78% decrease in
the number of AK lesions. This is comparable to
the corresponding decrease in lesion count of
approximately 70% observed in a
non-interventional study of 1051 patients [20].
Table 2 LS mean change from baseline in DLQI questionnaire scores at week 12 and 8 weeks after end of treatment
5-FU/SA (N5 108) Vehicle (N5 55) P value
DLQI total score
Week 12 0.53 -0.327 0.0052
8 Weeks post-treatment -0.667 -0.133 0.0725
Daily activities
Week 12 0.117 -0.041 0.0564
8 Weeks post-treatment -0.049 0.167 0.0294
Leisure
Week 12 0.105 -0.061 0.109
8 Weeks post-treatment -0.036 -0.005 0.6595
Personal relationships
Week 12 0.008 -0.083 0.1108
8 Weeks post-treatment -0.076 0.005 0.0934
Symptoms and feelings
Week 12 0.194 -0.248 0.0084
8 Weeks post-treatment -0.488 -0.339 0.3209
Treatment
Week 12 0.089 0.166 0.2729
8 Weeks post-treatment 0.001 -0.007 0.8854
Work and school
Week 12 0.001 -0.02 0.4985
8 Weeks post-treatment -0.032 0.07 0.0371
Analysis was based on an ANCOVA model in the change from baseline in total score and individual domains of the DLQI
questionnaire adjusted by the correspondent baseline as covariate and treatment group and anatomical site as factors. The
DLQI is calculated by summing the score of each question, resulting in a maximum of 30 and a minimum of 0. The higher
the score, the more quality of life is impaired. In the 5-FU/SA group, for all scores n = 91–92 at week 12 and n = 100–101
at 8 weeks post treatment; in the vehicle group n = 50–51 at week 12 and n = 53–54 at 8 weeks post-treatment
5-FU/SA 5-ﬂuorouracil 0.5%/salicylic acid 10%, ANCOVA analysis of covariance, DLQI Dermatology Life Quality Index,
LS least squares
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It should be borne in mind that 48.6% (498/
1025) of patients in the study by Szeimies and
colleagues received 5-FU 0.5%/salicylic acid
10% treatment for less than 6 weeks, which
may account for the slight difference in lesion
count reduction.
Given that treatment with 5-FU 0.5%/
salicylic acid 10% was associated with a greater
number of lesions transitioning from grade I/II
to grade 0 than with vehicle, this suggests that
active treatment affects the histopathology of
the AK lesions. Two small (case series) studies
using RCM recently determined that
field-directed 5-FU 0.5%/salicylic acid 10% for
up to 6 weeks of treatment was effective not
only for investigating the transitioning of
clinically visible lesions from a higher to lower
grade, but also for clearing sub-clinical lesions
after field-directed treatment [21, 22]. The
results from the RCM sub-study in a group of
30 patients from the current study will be
published separately.
Table 3 Incidence of TEAEs according to preferred term (safety population)
TEAE, n (%)a 5-FU/SA (N5 108) Vehicle (N5 55) Total (N5 163)
Application site
Erythema 96 (88.9) 29 (52.7) 125 (76.7)
Pain 75 (69.4) 23 (41.8) 98 (60.1)
Irritation 64 (59.3) 15 (27.3) 79 (48.5)
Inﬂammation 60 (55.6) 15 (27.3) 75 (46.0)
Scab 63 (58.3) 12 (21.8) 75 (46.0)
Erosion 46 (42.6) 6 (10.9) 52 (31.9)
Pruritus 36 (33.3) 16 (29.1) 52 (31.9)
Dermatitis 34 (31.5) 3 (5.5) 37 (22.7)
Bleeding 26 (24.1) 3 (5.5) 29 (17.8)
Edema 17 (15.7) 0 (0.0) 17 (10.4)
Ulcer 3 (2.8) 0 (0.0) 3 (1.8)
Application-site exfoliationb 6 (5.6) 3 (5.5) 9 (5.5)
Nasopharyngitisc,d 12 (11.1) 2 (3.6) 14 (8.6)
Nasopharyngitisc,e 4 (3.7) 1 (1.8) 5 (3.1)
Headache 4 (3.7) 2 (3.6) 6 (3.7)
Includes predeﬁned local skin reactions (application-site TEAEs) that were anticipated from the known safety proﬁle of
5-FU/SA
5-FU/SA 5-ﬂuorouracil 0.5%/salicylic acid 10%, TEAE treatment-emergent adverse event
a All events occurred B30 days after the ﬁnal treatment application
b Local skin reaction
c Nasopharyngitis identiﬁed from different system organ class high-level term
d Upper respiratory tract infection
e Upper respiratory tract infection, not elsewhere classiﬁed
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At 8 weeks after the end of treatment, PGA of
treatment efficacy was rated as ‘‘very good’’ or
‘‘good’’ in 90.2% of patients receiving 5-FU
0.5%/salicylic acid 10%. This was similar to
the 89% reported in the non-interventional
study by Szeimies and colleagues [20]. Overall
treatment satisfaction, as measured using the
TSQM questionnaire, was greater among
patients in the 5-FU 0.5%/salicylic acid 10%
arm than in the vehicle arm (P = 0.0019), as was
satisfaction in relation to treatment
effectiveness (P = 0.0064). In the 12-month
follow-up study by Stockfleth et al., it was
reported that 93.2% of patients receiving 5-FU
0.5%/salicylic acid 10% assessed treatment
efficacy as ‘‘very good’’ or ‘‘good’’ compared
with 81.6% in the diclofenac 3% in hyaluronic
acid group and 66.7% in the vehicle group [16].
Although improvement in DLQI total score was
statistically higher for vehicle versus 5-FU 0.5%/
salicylic acid 10% during the treatment phase,
this switched in favor of 5-FU 0.5%/salicylic
acid 10% 8 weeks after the end of treatment and
was attributed to local skin reactions associated
with 5-FU 0.5%/salicylic acid 10%.
Safety data in our study were consistent with
the known and predictable tolerability profile of
5-FU 0.5%/salicylic acid 10% [15, 16]. As with
other topical treatments for AK [23, 24], 5-FU
0.5%/salicylic acid 10% caused
administration-site reactions, such as
erythema, inflammation, and scabbing, prior
to demonstrating clear evidence of efficacy.
Based on our clinical experience and with the
vast majority of topical treatments for AK, local
adverse effects are expected and proportionally
correlate with treatment duration and efficacy.
For some patients who withdrew from
treatment, administration-site local skins
reactions were mentioned but not cited as the
main reason for drug withdrawal; six patients
(5.6%) in the 5-FU 0.5%/salicylic acid 10%
group and two patients (3.6%) in the vehicle
group. The number of patients for whom the
investigator considered that administration-site
local skin reactions justified treatment
discontinuation was low (5-FU 0.5%/salicylic
acid 10% arm: n = 1; vehicle arm: n = 0).
Conservatively taking these numbers into
account, treatment discontinuation rates due
to safety/tolerability issues were low in this
study.
One potential limitation of our study was
the higher incidence of local skin reactions in
the 5-FU 0.5%/salicylic acid 10% arm, which
may have compromised the blinding of the
study. However, the incidence of local skin
reactions in the vehicle group, which are
similar to those reported previously in a
pivotal clinical trial using a lesion-directed
approach [15] and may have been linked to
the irritant effects of dimethyl sulfoxide that
are part of the known safety profile of 5-FU
0.5%/salicylic acid 10% [13], minimized the
unblinding risk. Also, during the 8-week period
after the end of treatment, patients were
expected not to use further treatments for AK
lesions, which may have proven difficult for
some patients. However, the specification that
patients had grade I/II lesions, rather than
more severe AK, may have helped avoid the
situation where additional treatment was
required. While it is clearly important to
evaluate clinical endpoints, selecting
endpoints that only included clinical
evaluation of lesions could be regarded as a
potential limitation of the study. Good
correlation between routine histology and the
results of RCM, a novel non-invasive imaging
technique that allows the in vivo evaluation of
skin at near-histological resolution, has been
reported previously [25]. Results from the RCM
sub-study in a group of 30 patients from the
current study will be published separately.
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A strength of the present study was the
inclusion of patients with hyperkeratotic
lesions, which enables demonstration of the
efficacy of 5-FU 0.5%/salicylic acid 10% against
these more clinically severe lesions. In addition,
the findings from this first randomized study
with field-directed therapy with 5-FU/SA are
robust, with consistency across all reported
variables, both objectively measured and
patient-reported.
CONCLUSION
In this randomized, double-blind,
vehicle-controlled study, once-daily topical
treatment with field-directed 5-FU 0.5%/
salicylic acid 10% applied over a 12-week
period was an effective treatment for grade I
and II AK lesions. Furthermore, treatment was
well accepted by both physicians and patients
in terms of overall treatment satisfaction and
clinical outcomes. In addition, safety outcomes
were consistent with the known and
predictable safety profile of 5-FU 0.5%/salicylic
acid 10%.
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